The drug is known as T-DM1, and if approved, could hit the market as early as next year, according to an article by The New York Times.
The new drug represents an advance in treating breast cancer, and the success in the clinical trials show that it’s possible to deliver the drug to cancerous cells while at the same time saving healthy ones.
T-DM1 and other similar drugs being tested consist of antibodies, which are powerful toxins linked to proteins. The antibodies from the drugs grab on to cancer cells and directly deliver the toxins to it.
Side effects of the drugs are reduced as the toxins are not active until it reaches the tumor.
In the trials, it was seen that T-DM1 delayed the worsening of breast cancer by about three months. Also, approximately 85 percent of patients receiving the new drug were still alive after one year, compared to the control group which had a percentage of 77.
Snyder and Wenner, P.C.
2200 E. Camelback Road
Phoenix, AZ 85016